Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to US Food and Drug Administration approval.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Vendors such as Color Health promise to save employers money by helping workers catch cancer sooner, but these initiatives ...